Therapeutic Potential for Targeting Autophagy in ER+ Breast Cancer

SIMPLE SUMMARY: While ER+ breast cancer is generally considered to have a better prognosis than other breast cancer subtypes, relapse may nevertheless occur years after diagnosis and treatment. Despite initially responding to treatment, 30–40% of tumors acquire resistance to treatment that contribut...

Descripción completa

Detalles Bibliográficos
Autores principales: Finnegan, Ryan M., Elshazly, Ahmed M., Schoenlein, Patricia V., Gewirtz, David A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9454809/
https://www.ncbi.nlm.nih.gov/pubmed/36077830
http://dx.doi.org/10.3390/cancers14174289

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9454809/
https://www.ncbi.nlm.nih.gov/pubmed/36077830
http://dx.doi.org/10.3390/cancers14174289

Ejemplares similares